Rigel Pharmaceuticals
RIGL
152 hedge funds and large institutions have $493M invested in Rigel Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 42 increasing their positions, 54 reducing their positions, and 23 closing their positions.
22% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 23
2% more funds holding
Funds holding: 149 → 152 (+3)
2% more call options, than puts
Call options by funds: $2.2M | Put options by funds: $2.16M
1% more capital invested
Capital invested by funds: $489M → $493M (+$3.48M)
0.2% more ownership
Funds ownership: 8.28% → 8.48% (+0.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
22% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 54
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$19.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$12.5M |
| 4 |
Millennium Management
New York
|
+$10.5M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$19.8M |
| 2 |
Morgan Stanley
New York
|
-$15.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$12.1M |
| 4 |
Renaissance Technologies
New York
|
-$7.4M |
| 5 |
Goldman Sachs
New York
|
-$5.13M |
RIGL Hedge Fund Activity: Q1 2021 in Review
152 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q1 2021, worth a combined $493M — up 0.71% from $489M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new RIGL positions and 23 closed out — a net gain of 5 holders — while 42 added to existing stakes and 54 trimmed.
The largest buyer was Lord, Abbett & Co, opening a new position worth an estimated $19.2M. The largest seller was Wellington Management Group, cutting an estimated $19.8M.
- 152 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q1 2021, up from 149 in Q4 2020.
- Funds reported $493M of Rigel Pharmaceuticals stock for Q1 2021, up 0.71% quarter-over-quarter.
- 28 funds opened new Rigel Pharmaceuticals positions in Q1 2021 and 23 closed out, a net change of +5 holders.
- The largest Rigel Pharmaceuticals buyer in Q1 2021 was Lord, Abbett & Co, an estimated $19.2M added.
- The largest Rigel Pharmaceuticals seller in Q1 2021 was Wellington Management Group, an estimated $19.8M sold.
Based on aggregated 13F filings for Q1 2021.